QuantalX Neuroscience, an innovative healthcare company dedicated to the early detection of brain disorders, has reached a significant milestone as part of its pre-commercialization strategy in the United States. The recent assignment of a Current Procedural Terminology (CPT) code underscores the importance of Delphi-MD, the company's cutting-edge technology, in the realm of early brain health assessment.

Delphi-MD stands out as a first-of-its-kind automated Direct Neuro-Physiological technology designed to identify and assess brain abnormalities while predicting treatment responses. An exceptional feature of this technology is that it operates without active patient involvement, using safe magnetic stimulation to reveal individual neuronal signatures indicative of normal or abnormal brain function. This results in an immediate clinical report that empowers physicians to make informed treatment decisions.

Delphi-MD has received Breakthrough FDA Designation for two distinct applications. The first designation is centered on the early identification of patients at risk of dementia and stroke, offering insights into functional and structural brain abnormalities associated with the early stages of neurodegeneration. The second designation pertains to the diagnosis of patients with Normal Pressure Hydrocephalus (NPH) and the prediction of their response to ventriculoperitoneal shunting (VPS) surgery.

The benefits of Delphi-MD are numerous, benefiting both neurologists and the healthcare system. Its objective and automated approach streamlines brain health assessments, reducing the need for time-consuming and potentially inaccurate evaluations, as well as costly MRI or CT scans.

Furthermore, the assignment of the CPT code ensures that Delphi-MD will receive appropriate reimbursement, which is expected to promote its widespread adoption. This technology not only improves patient care but also offers financial advantages to payors and healthcare systems through preventative care and risk adjustment measures.

Source: prnewswire.com

 

Report Abuse